Featured Research

from universities, journals, and other organizations

Higher doses of fulvestrant prolonged survival in patients with advanced breast cancer

Date:
December 5, 2012
Source:
CRRC-AACR San Antonio Breast Cancer Symposium
Summary:
Increasing the dose of fulvestrant from 250 mg to 500 mg improved median overall survival in women with locally advanced or metastatic estrogen receptor-positive breast cancer, according to updated data.

Increasing the dose of fulvestrant from 250 mg to 500 mg improved median overall survival in women with locally advanced or metastatic estrogen receptor-positive breast cancer, according to updated data from the CONFIRM trial presented at the 2012 CTRC-AACR San Antonio Breast Cancer Symposium, held Dec. 4-8.

Related Articles


The Comparison of Faslodex in Recurrent or Metastatic Breast Cancer (CONFIRM) trial is a randomized, double-blind, parallel-group, multicenter, phase III trial of postmenopausal women with estrogen receptor (ER)-positive advanced breast cancer that recurred or progressed following endocrine therapy.

"Of note, the improvement in survival with the higher dose of fulvestrant was achieved without increasing treatment toxicity. Indeed, the dose of 500 mg had the same toxicity profile as the 250-mg dose," said Angelo Di Leo, M.D., Ph.D., head of the department of medical oncology at the Hospital of Prato, Istituto Toscano Tumori in Prato, Italy.

Between February 2005 and August 2007, researchers randomly assigned 736 women from 128 centers in 17 countries to 250 mg or 500 mg of fulvestrant and followed them until 75 percent of the patients died. At the time of analysis, 554 patients had died, 63 were lost to follow-up and 16 withdrew consent.

Among the entire study population, the 500-mg dose was associated with a clinically relevant 4.1-month difference in median overall survival compared with the lower dose: 26.4 months in the 500-mg group and 22.3 months in the 250-mg group. Researchers also saw a 19 percent reduction in risk for death in the 500-mg group compared with the 250-mg group. Serious adverse events occurred in 8.9 percent of patients who had received the 500-mg dose and in 6.7 percent of patients in the 250-mg group.

"For those postmenopausal women with recurrent or progressing ER-positive locally advanced or metastatic breast cancer for whom fulvestrant is the appropriate treatment choice, the standard of care is a 250-mg dose," said Di Leo. "Our results indicate that this should be modified to a 500-mg dose."

According to Di Leo, the next research step will be to study 500 mg of fulvestrant in combination with biological agents, such as PI3K inhibitors or anti-HER2 agents that can reverse resistance to endocrine therapy.

"This approach could further increase the activity of fulvestrant given at the 500-mg dose," he said.


Story Source:

The above story is based on materials provided by CRRC-AACR San Antonio Breast Cancer Symposium. Note: Materials may be edited for content and length.


Cite This Page:

CRRC-AACR San Antonio Breast Cancer Symposium. "Higher doses of fulvestrant prolonged survival in patients with advanced breast cancer." ScienceDaily. ScienceDaily, 5 December 2012. <www.sciencedaily.com/releases/2012/12/121205090909.htm>.
CRRC-AACR San Antonio Breast Cancer Symposium. (2012, December 5). Higher doses of fulvestrant prolonged survival in patients with advanced breast cancer. ScienceDaily. Retrieved December 20, 2014 from www.sciencedaily.com/releases/2012/12/121205090909.htm
CRRC-AACR San Antonio Breast Cancer Symposium. "Higher doses of fulvestrant prolonged survival in patients with advanced breast cancer." ScienceDaily. www.sciencedaily.com/releases/2012/12/121205090909.htm (accessed December 20, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Saturday, December 20, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

The Best Tips to Curb Holiday Carbs

The Best Tips to Curb Holiday Carbs

Buzz60 (Dec. 19, 2014) It's hard to resist those delicious but fattening carbs we all crave during the winter months, but there are some ways to stay satisfied without consuming the extra calories. Vanessa Freeman (@VanessaFreeTV) has the details. Video provided by Buzz60
Powered by NewsLook.com
Sierra Leone Bikers Spread the Message to Fight Ebola

Sierra Leone Bikers Spread the Message to Fight Ebola

AFP (Dec. 19, 2014) More than 100 motorcyclists hit the road to spread awareness messages about Ebola. Nearly 7,000 people have now died from the virus, almost all of them in west Africa, according to the World Health Organization. Video provided by AFP
Powered by NewsLook.com
Researchers Test Colombian Village With High Alzheimer's Rates

Researchers Test Colombian Village With High Alzheimer's Rates

AFP (Dec. 19, 2014) In Yarumal, a village in N. Colombia, Alzheimer's has ravaged a disproportionately large number of families. A genetic "curse" that may pave the way for research on how to treat the disease that claims a new victim every four seconds. Duration: 02:42 Video provided by AFP
Powered by NewsLook.com
Double-Amputee Becomes First To Move Two Prosthetic Arms With His Mind

Double-Amputee Becomes First To Move Two Prosthetic Arms With His Mind

Buzz60 (Dec. 19, 2014) A double-amputee makes history by becoming the first person to wear and operate two prosthetic arms using only his mind. Jen Markham has the story. Video provided by Buzz60
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins